The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections
- PMID: 13679322
- DOI: 10.7326/0003-4819-139-6-200309160-00008
The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections
Abstract
Background: The relationship between previous antimicrobial treatments and infection with drug-resistant Helicobacter pylori is unknown.
Objectives: To determine whether previous use of antimicrobial agents predicts subsequent antibiotic resistance of H. pylori and whether resistance affects treatment outcome.
Design: Retrospective cohort analysis of adults recruited sequentially from a clinical practice.
Setting: A referral hospital in Anchorage, Alaska.
Patients: 125 adults infected with H. pylori.
Measurements: Medical records were reviewed for antimicrobial agents prescribed in the 10 years before diagnosis with H. pylori infection. Antimicrobial susceptibility of H. pylori isolates obtained from endoscopic gastric biopsy was determined by using agar dilution. Cure was determined by using the urea breath test 2 months after antimicrobial treatment.
Results: Among the 125 patients, 37 (30%) were found to have H. pylori isolates resistant to clarithromycin and 83 (66%) were found to have H. pylori isolates resistant to metronidazole. Resistance to clarithromycin was associated with previous use of any macrolide antibiotic (P < 0.001), and resistance to metronidazole was associated with previous use of metronidazole (P < 0.001). The odds of isolates being resistant to clarithromycin increased in relation to the number of courses of macrolides received (P < 0.001). Among 53 persons treated with clarithromycin-based regimens, treatment failed in 77% of those carrying clarithromycin-resistant H. pylori (10 of 13) and 13% of those with clarithromycin-susceptible strains (5 of 40) (relative risk, 6.2 [95% CI, 1.9 to 37.1]; P < 0.001).
Conclusions: Previous use of macrolides and metronidazole is associated with H. pylori resistant to these antimicrobial agents. Clarithromycin resistance is associated with a greater risk for failure with clarithromycin-based treatments.
Comment in
-
Collateral damage.Ann Intern Med. 2003 Sep 16;139(6):523-4. doi: 10.7326/0003-4819-139-6-200309160-00017. Ann Intern Med. 2003. PMID: 13679331 No abstract available.
-
Summaries for patients. Past antibiotic use affects resistance and outcomes of Helicobacter pylori infection.Ann Intern Med. 2003 Sep 16;139(6):I10. doi: 10.7326/0003-4819-139-6-200309160-00001. Ann Intern Med. 2003. PMID: 13679344 No abstract available.
-
The past determines the future.Gastroenterology. 2004 Apr;126(4):1202-4. doi: 10.1053/j.gastro.2003.11.063. Gastroenterology. 2004. PMID: 15057761 No abstract available.
-
What's bugging you?Gastroenterology. 2004 Apr;126(4):1204-5. doi: 10.1053/j.gastro.2003.10.090. Gastroenterology. 2004. PMID: 15057762 No abstract available.
-
Risk factors for Helicobacter pylori resistance.Ann Intern Med. 2004 Jun 1;140(11):931; author reply 931. doi: 10.7326/0003-4819-140-11-200406010-00018. Ann Intern Med. 2004. PMID: 15172911 No abstract available.
-
The potential dangers of test-and-treat strategies directed at H. pylori.Rev Gastroenterol Disord. 2004 Spring;4(2):94-5. Rev Gastroenterol Disord. 2004. PMID: 15185722 No abstract available.
Similar articles
-
[Antibiotic resistance of Helicobacter pylori: prevalence in one region in the southern Netherlands and implications for treatment].Ned Tijdschr Geneeskd. 2014;158:A7501. Ned Tijdschr Geneeskd. 2014. PMID: 25159698 Dutch.
-
Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.Helicobacter. 2018 Jun;23(3):e12485. doi: 10.1111/hel.12485. Epub 2018 Apr 25. Helicobacter. 2018. PMID: 29696736 Clinical Trial.
-
Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.Helicobacter. 2012 Aug;17(4):269-76. doi: 10.1111/j.1523-5378.2012.00947.x. Epub 2012 Mar 30. Helicobacter. 2012. PMID: 22759326 Clinical Trial.
-
Helicobacter pylori antimicrobial resistance in Melbourne, Australia. Time to review therapeutic guidelines?Intern Med J. 2021 Nov;51(11):1919-1926. doi: 10.1111/imj.15355. Intern Med J. 2021. PMID: 33977647 Review.
-
Nontraditional therapies to treat Helicobacter pylori infection.J Microbiol. 2014 Apr;52(4):259-72. doi: 10.1007/s12275-014-3603-5. Epub 2014 Mar 29. J Microbiol. 2014. PMID: 24682990 Review.
Cited by
-
Optimizing Helicobacter pylori Treatment: An Updated Review of Empirical and Susceptibility Test-Based Treatments.Gut Liver. 2023 Sep 15;17(5):684-697. doi: 10.5009/gnl220429. Epub 2023 Feb 27. Gut Liver. 2023. PMID: 36843419 Free PMC article. Review.
-
A Bioluminescence-Based Drug Screen Identifies Activities of Fexinidazole and Its Metabolites against Helicobacter pylori.Antibiotics (Basel). 2022 Nov 11;11(11):1605. doi: 10.3390/antibiotics11111605. Antibiotics (Basel). 2022. PMID: 36421252 Free PMC article.
-
Clinical Factors Implicated in Antibiotic Resistance in Helicobacter pylori Patients.Microorganisms. 2022 Jan 29;10(2):322. doi: 10.3390/microorganisms10020322. Microorganisms. 2022. PMID: 35208776 Free PMC article. Review.
-
Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship.Therap Adv Gastroenterol. 2021 Dec 21;14:17562848211064080. doi: 10.1177/17562848211064080. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34987609 Free PMC article. Review.
-
The Alaska Native Tumour Registry: fifty years of cancer surveillance data for Alaska Native people.Int J Circumpolar Health. 2022 Dec;81(1):2013403. doi: 10.1080/22423982.2021.2013403. Int J Circumpolar Health. 2022. PMID: 34918619 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical